Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025Blood

Circulating CD161high CD8 T cells at leukapheresis are associated with reduced risk of progression at 12 months (PFS12) in large B-cell lymphoma treated by axicabtagene ciloleucel: Results from the Phase 2 alycante study (LYSA)

View Full Paper
Ask AI
Bookmark
Share

Authors

SGSimon Le GallouDRDelphine RossilleACAlexis Claudel

Discussion

Loading...

Member takes

Overview

Observational analysis identified immune biomarkers at leukapheresis tied to efficacy in large B-cell lymphoma, suggesting new predictive strategies.

Key Points

  • Reduced risk of progression at 12 months was linked to specific immune cell signatures in patients.
  • Higher metabolic response at 3 months was observed in 71% of the cohort, with immunological factors at leukapheresis.
  • Analysis using mass cytometry identified immune cell subsets associated with clinical outcomes and treatment efficacy.
  • Identifying these biomarkers may enhance the stratification of patients for targeted CAR T-cell therapies.

Cite This Study

Gallou et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236dafahttps://doi.org/10.1182/blood-2025-5332
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Pre-manufacturing CD8+ central-memory type 2 T cells predict axicabtagene ciloleucel failure in large B-cell lymphoma2025
  2. 2Prognostic impact of CAR-T cell expansion and PD1 expression in patients with DLBCL treated with axicabtagene ciloleucel2025
  3. 3Immune landscape characterization of relapsed/refractory B-cell lymphoma patients treated with CD19 CAR-T cell therapy2025
  4. 4Lymphocyte kinetics as a predictor of clinical outcomes following CAR-T therapy for non-Hodgkin lymphoma2025
  5. 5Correlation of T cell fitness of apheresis products with response to CAR T-cell therapy in patients with relapsed or refractory large B-cell lymphoma: A prospective observational study at a single center2025